Description

CJC-1295 DAC represents an advanced formulation of the synthetic growth hormone-releasing hormone analogue incorporating a Drug Affinity Complex (DAC) modification designed to significantly extend the peptide’s half-life and duration of action. The DAC modification consists of a maleimidopropionic acid-lysine conjugation at the C-terminus, which enables specific binding to albumin proteins and substantially prolongs the compound’s presence in biological systems. This modification allows for sustained growth hormone-releasing activity over extended periods, making it particularly valuable for research protocols requiring prolonged GHRH receptor activation. The compound maintains all the structural benefits of standard CJC-1295, including enhanced resistance to enzymatic degradation and optimized receptor binding affinity, while providing the additional advantage of extended biological activity. Research applications include investigation of sustained growth hormone regulation, long-term pituitary function studies, and examination of extended GHRH signaling effects. For research use only.